logo
CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority

CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority

Yahoo05-06-2025
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," 'Inspira Technologies,' or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the 'ART100 system'), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations.
this ramp up strategic production aims to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs.
'We are preparing for commercial execution,' said Dagi Ben Noon, Chief Executive Officer of Inspira Technologies. 'Our dialogue with a European government body has advanced to a stage where operational readiness is essential. Expanding our production capacity will enable us to meet projected deployment needs quickly and efficiently.'
This move follows Inspira's recent announcement of its global rollout strategy and reflects the Company's commitment to fast-track revenue generation from the ART100 system, while continuing its development of its next-generation platforms, the ART500 and the HYLA™ blood sensor.
The Company believes the current momentum—combined with a growing global focus on scalable respiratory solutions—may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a technological foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the critical care and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that it expects demand for its ART100 system from a European governmental authority, that it has ramped up its production in order to meet expected near term delivery needs, , the benefits and advantages of the ART100, that the ART100 system is gaining traction as a reliable device for a critical care and emergency preparedness programs, the potential outcome of its procurement negotiations with a European government authority, its belief that expanding its production capacity enables the Company to meet projected deployment needs quickly and efficiently, and its belief that current momentum may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.
Company ContactInspira Technologies – Media RelationsEmail: info@inspirao2.comPhone: +972-9-9664485
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CNBC Daily Open: OpenAI CEO, who sparked AI frenzy, worries about AI bubble
CNBC Daily Open: OpenAI CEO, who sparked AI frenzy, worries about AI bubble

CNBC

time12 minutes ago

  • CNBC

CNBC Daily Open: OpenAI CEO, who sparked AI frenzy, worries about AI bubble

There's a bubble forming in the artificial intelligence industry, according to OpenAI CEO Sam Altman. "Are we in a phase where investors as a whole are overexcited about AI? My opinion is yes. Is AI the most important thing to happen in a very long time? My opinion is also yes," Altman said. "I'm sure someone's gonna write some sensational headline about that. I wish you wouldn't, but that's fine," he added. (Apologies to Altman.) Altman's AI company is currently in talks to sell about $6 billion in stock that would value OpenAI at around $500 billion, CNBC confirmed Friday. In another conversation, Altman warned that the U.S. may be underestimating the progress that China is making in AI. Given the above premises, should investors be more cautious about OpenAI? Altman was not posed this question, but one wonders whether his opinion would also be "yes." Outside pure-play AI companies, the money is, likewise, still flowing. Intel is receiving a $2 billion injection of cash from Japan's SoftBank. It's a much-needed boost to the beleaguered U.S. chipmaker. Intel has fallen behind foreign rivals such as TSMC and Samsung in manufacturing semiconductors that serve as the brains for AI models. But going by Altman's views, the investment in Intel might not be a good bet by SoftBank CEO Masayoshi Son. Not everyone agrees with Altman, of course. Wedbush's Dan Ives told CNBC on Monday that there might be "some froth" in parts of the market, but "the actual impact over the medium and long term is actually being underestimated." And Ray Wang, research director for semiconductors, supply chain and emerging technology at Futurum Group, pointed out that the AI industry is not heterogeneous. There are market leaders, and then there are companies that are still developing. In the real world, bubbles delight because they reflect their surroundings in a play of light. But the bubble Altman described could be one doesn't show the face of its meeting paves the way for trilateral talks with Putin. At the White House meeting, the U.S. president also discussed security guarantees for Ukraine — which would reportedly involve a purchase around $90 billion of American weapons by Kyiv. Intel is getting a $2 billion investment from SoftBank. Both companies announced the development Monday, in which SoftBank will pay $23 per share for Intel's common stock. Shares of Intel jumped more than 5% in extended trading. The artificial intelligence market is in a bubble, says Sam Altman. Separately, the OpenAI CEO said he's "worried about China," and that the U.S. may be underestimating the latter's progress in artificial intelligence. U.S. stocks close mostly flat on Monday. The three major indexes made moves that were less than 0.1 percentage pointsin either direction as investors await key U.S. retail earnings. Asia-Pacific markets were mixed Tuesday. SoftBank shares fell as much as 5.7%. [PRO] Opportunities in one area of the European market. Investors have been pivoting away from the U.S. as multiple European indexes outperform those on Wall Street. But one pocket of Europe still remains overlooked, according to analysts. American money pours into Europe's soccer giants as club valuations soar European soccer is a bigger business than ever, with clubs in the continent's five top leagues raking in 20.4 billion euros ($23.7 billion) in revenue in the 2023-2024 season. American investors have been eyeing a piece of that pie. U.S. investors now own, fully or in part, the majority of soccer teams in England's Premier League. That now includes four of the traditional Big Six clubs, with Chelsea, Liverpool, Manchester United and Arsenal all attracting U.S. investment.

Coloplast A/S – Interim Financial Report, 9M 2024/25
Coloplast A/S – Interim Financial Report, 9M 2024/25

Business Upturn

time42 minutes ago

  • Business Upturn

Coloplast A/S – Interim Financial Report, 9M 2024/25

By GlobeNewswire Published on August 19, 2025, 10:33 IST 2024/25 Interim financial results, 9M 2024/25 1 October 2024 – 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT 1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin 1,2 was 28%, against 27% last year. was DKK 1,915 million, a 2% increase from last year. The EBIT margin was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT 1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin 1 was 27%, on par with last year 2 . was DKK 5,718 million, a 4% increase from last year. The EBIT margin was 27%, on par with last year . Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. 'We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast – 9M 2024/25 conference call For further information, please contact Investors and analysts Anders Lonning-SkovgaardExecutive Vice President, CFO Tel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Press and media Peter MønsterSr. Media Relations ManagerTel. +45 4911 2623 Email: [email protected] Address Coloplast A/SHoltedam 1DK-3050 HumlebaekDenmark Company reg. (CVR) no. 69749917 Website This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_release Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Dollar bides times as markets brace for Ukraine summit
Dollar bides times as markets brace for Ukraine summit

CNBC

timean hour ago

  • CNBC

Dollar bides times as markets brace for Ukraine summit

The U.S. dollar held steady against its major peers on Tuesday as global markets awaited the outcome of a White House summit with European nations that could determine the next phase of the war in Ukraine. The dollar index rose 0.31% to 98.122 with geopolitical events taking center stage, after U.S. President Donald Trump told President Volodymyr Zelenskiy on Monday that the United States would help guarantee Ukraine's security in any deal to end the war with Russia. "At the moment, markets are cautious," said Tina Teng, an independent market analyst in Auckland, as traders weighed the possible implications for the global energy markets. "The U.S. dollar is going stronger against other currencies and the risk-on sentiment is still leading markets at the moment," she added, citing stock indexes at record highs. The euro held steady at $1.1667, up 0.06% so far in Asia, shuffling along the midpoint of the trading range it has sat in for the past two weeks. Markets are seeking direction this week from the Federal Reserve's annual symposium in Jackson Hole on the likely path of interest rates. Fed Chair Jerome Powell is due to speak on the economic outlook and the central bank's policy framework. Many investors are away for summer holidays in the northern hemisphere, while markets will be left with few catalysts amid a thin diary of data releases on Tuesday. Cryptocurrencies bucked the trend, with bitcoin falling 0.3% to notch a third straight day of declines after hitting a record high on Thursday. Ether sank 0.6%, extending losses for a second day after failing to breach a record high last week. Against the yen, the dollar was at 147.835 yen, unchanged from late U.S. levels and nearing the top of the trading channel it has sat in all month. Japanese stock markets advanced in early trading on Tuesday, with both the Nikkei 225 and the Topix at record levels. The Australian dollar fetched $0.6495, up 0.1% in early trade, after Westpac's consumer sentiment data for August rose to a 3-1/2-year high. The kiwi tacked on 0.1% to $0.59245. Sterling traded at $1.351, up 0.1% so far on the day, after rebounding from the low end of its range recorded over the past week.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store